Perspectives and challenges of interferon-free therapy for chronic hepatitis C

Journal of Hepatology

Volumn 58, Issue 3, 2013, Pages 583-592

  Lange, Christian M ^a   Zeuzem, Stefan ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

All oral therapy; Antiviral therapy; Directly acting antiviral agent; Hepatitis C virus; Null responder

Indexed keywords

ABT 333; ABT 450; ALISPORIVIR; ASUNAPREVIR; BALAPIRAVIR; BI 207127; BOCEPREVIR; CILUPREVIR; CYCLOSPORIN A [4 N METHYLISOLEUCINE]; DACLATASVIR; DANOPREVIR; FALDAPREVIR; FILIBUVIR; GS 9256; INTERFERON; LOMIBUVIR; MERICITABINE; MIRAVIRSEN; NARLAPREVIR; NESBUVIR; PEGINTERFERON ALPHA; RIBAVIRIN; SETROBUVIR; SIMEPREVIR; SOFOSBUVIR; TEGOBUVIR; TELAPREVIR; UNINDEXED DRUG; VALOPICITABINE; VANIPREVIR;

ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; DECOMPENSATED LIVER CIRRHOSIS; GENOTYPE; HEPATITIS C; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; REVIEW; VIRUS LOAD;

CLINICAL TRIALS AS TOPIC; CYCLOPHILINS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84874107832     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.10.019     Document Type: Review

References (67)

1. B.R. Bacon, S.C. Gordon, E. Lawitz, P. Marcellin, J.M. Vierling, and S. Zeuzem Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
2. I.M. Jacobson, J.G. McHutchison, G. Dusheiko, A.M. Di Bisceglie, K.R. Reddy, and N.H. Bzowej Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
3. F. Poordad, J. McCone Jr., B.R. Bacon, S. Bruno, M.P. Manns, and M.S. Sulkowski Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
4. S. Zeuzem, P. Andreone, S. Pol, E. Lawitz, M. Diago, and S. Roberts Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
5. C.M. Lange, C. Sarrazin, and S. Zeuzem Review article: specifically targeted anti-viral therapy for hepatitis C-a new era in therapy Aliment Pharmacol Ther 32 2010 14 28
6. A.S. Lok, D.F. Gardiner, E. Lawitz, C. Martorell, G.T. Everson, and R. Ghalib Preliminary study of two antiviral agents for hepatitis C genotype 1 N Engl J Med 366 2012 216 224
7. K. Chayama, S. Takahashi, J. Toyota, Y. Karino, K. Ikeda, and H. Ishikawa Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders Hepatology 55 2012 742 748
8. Nature Outlook Hepatitis C Nature 474 2011 S1 S21
9. K. Morikawa, C.M. Lange, J. Gouttenoire, E. Meylan, V. Brass, and F. Penin Nonstructural protein 3-4A: the Swiss army knife of hepatitis C virus J Viral Hepat 18 2011 305 315
10. N. Forestier, H.W. Reesink, C.J. Weegink, L. McNair, T.L. Kieffer, and H.M. Chu Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C Hepatology 46 2007 640 648
11. C. Sarrazin, T.L. Kieffer, D. Bartels, B. Hanzelka, U. Muh, and M. Welker Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir Gastroenterology 132 2007 1767 1777
12. C. Sarrazin, R. Rouzier, F. Wagner, N. Forestier, D. Larrey, and S.K. Gupta SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders Gastroenterology 132 2007 1270 1278
13. S. Susser, C. Welsch, Y. Wang, M. Zettler, F.S. Domingues, and U. Karey Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients Hepatology 50 2009 1709 1718
14. D.M. Brainard, A. Petry, K. Van Dyck, R. Nachbar, I.M. De Lepeleire, and L. Caro Safety and antiviral activity of MK-5172, a novel HCV NS3/4A protease inhibitor with potent activity against known resistance mutants, in genotype 1 and 3 HCV-infected patients Hepatology 52 2010 706
15. H.W. Reesink, G.C. Fanning, K.A. Farha, C. Weegink, A. Van Vliet, and G. Van 't Klooster Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients Gastroenterology 138 2010 913 921
16. V. Summa, S.W. Ludmerer, J.A. McCauley, C. Fandozzi, C. Burlein, and G. Claudio MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants Antimicrob Agents Chemother 56 2012 4161 4167
17. M.P. Manns, M. Bourliere, Y. Benhamou, S. Pol, M. Bonacini, and C. Trepo Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection J Hepatol 54 2011 1114 1122
18. C. Moreno, T. Berg, T. Tanwandee, S. Thongsawat, H. Van Vlierberghe, and S. Zeuzem Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study J Hepatol 56 2012 1247 1253
19. C. Sarrazin, and S. Zeuzem Resistance to direct antiviral agents in patients with hepatitis C virus infection Gastroenterology 138 2010 447 462
20. M.F. McCown, S. Rajyaguru, S. Kular, N. Cammack, and I. Najera GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796 Antimicrob Agents Chemother 53 2009 2129 2132
21. K.J. Wilby, E.D. Greanya, J.A. Ford, E.M. Yoshida, and N. Partovi A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients Ann Hepatol 11 2012 179 185
22. D. Moradpour, F. Penin, and C.M. Rice Replication of hepatitis C virus Nat Rev Microbiol 5 2007 453 463
23. M. Gao, R.E. Nettles, M. Belema, L.B. Snyder, V.N. Nguyen, and R.A. Fridell Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect Nature 465 2010 96 100
24. R.E. Nettles, M. Gao, M. Bifano, E. Chung, A. Persson, and T.C. Marbury Multiple ascending dose study of BMS-790052, an NS5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1 Hepatology 54 2011 1956 1965
25. R.A. Fridell, C. Wang, J.H. Sun, D.R. O'Boyle 2nd, P. Nower, and L. Valera Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations Hepatology 54 2011 1924 1935
26. S. Pol, R.H. Ghalib, V.K. Rustgi, C. Martorell, G.T. Everson, and H.A. Tatum Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial Lancet Infect Dis 12 2012 671 677
27. U. Koch, and F. Narjes Allosteric inhibition of the hepatitis C virus NS5B RNA dependent RNA polymerase Infect Disord Drug Targets 6 2006 31 41
28. Le Pogam S, Yan J, Chhabra M, Ilnicka M, Kang H, Kosaka A, et al. Characterization of HCV quasispecies dynamics upon short term dual-therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevir. Antimicrob Agents Chemother 2012 [epub].
29. J.M. Pawlotsky, I. Najera, and I. Jacobson Resistance to mericitabine, a nucleoside analogue inhibitor of HCV RNA-dependent RNA polymerase Antivir Ther 17 2012 411 423
30. E. Gane, P. Pockros, S. Zeuzem, P. Marcellin, A. Shikhman, and C. Bernaards Interferon-free treatment with a combination of mericitabine and danoprevir with or without ribavirin in treatment-naive HCV genotype 1-infected patients J Hepatol 56 2012 555 556
31. P. Pockros, D.M. Jensen, and N. Tsai First SVR data with the nucleoside analogue polymerase inhibitor mericitabine (RG7128) combined with peginterferon/ribavirin in treatment-naive HCV G1/4 patients: interim analysis of the JUMP-C trial J Hepatol 54 2011 538
32. E. Lawitz, J.P. Lalezari, T. Hassanein, K.V. Kowdley, F. Poordad, and A.M. Sheikh Once-daily PSI-7977 plus peg/RBV in treatment-naive patients with HCV GT1: robust end of treatment response rates are sustained post-treatment Hepatology 54 2011 113
33. K.V. Kowdley, E. Lawitz, I. Crespo, T. Hassanein, M. Davis, and D.R. De Mico ATOMIC: 97% RVR for PSI-7977 + PEG/RBV × 12 week regimen in HCV GT1: an end to response-guided therapy? J Hepatol 56 2012 1
34. P.L. Beaulieu Non-nucleoside inhibitors of the HCV NS5B polymerase: progress in the discovery and development of novel agents for the treatment of HCV infections Curr Opin Investig Drugs 8 2007 614 634
35. C.A. Lesburg, M.B. Cable, E. Ferrari, Z. Hong, A.F. Mannarino, and P.C. Weber Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site Nat Struct Biol 6 1999 937 943
36. F. Wagner, R. Thompson, C. Kantaridis, P. Simpson, P.J. Troke, and S. Jagannatha Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients Hepatology 54 2011 50 59
37. D. Larrey, A.W. Lohse, V. de Ledinghen, C. Trepo, T. Gerlach, and J.P. Zarski Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin J Hepatol 57 2012 39 46
38. P.J. Troke, M. Lewis, P. Simpson, K. Gore, J. Hammond, and C. Craig Characterization of resistance to the nonnucleoside NS5B inhibitor filibuvir in hepatitis C virus-infected patients Antimicrob Agents Chemother 56 2012 1331 1341
39. N. Afdhal, C. O'Brien, and E. Godofsky Valopicitabine alone or with PEG-interferon/ribavirin retreatment in patients with HCV-1 infection and prior non-response to PEGIFN/RBV: One-year results J Hepatol 46 2007 5
40. N.M. Kneteman, A.Y. Howe, T. Gao, J. Lewis, D. Pevear, and G. Lund HCV796: a selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus Hepatology 49 2009 745 752
41. S. Villano, D. Raible, D. Harper, J. Speth, P. Chandra, and P. Shaw Antiviral activity of the non-nucleoside polymerase inhibitor, HCV-796, in combination with pegylated interferon alfa-2b in treatment-naive patients with chronic HCV J Hepatol 46 2007 24
42. P.J. Pockros Drugs in development for chronic hepatitis C: a promising future Expert Opin Biol Ther 11 2011 1611 1622
43. A. Kaul, S. Stauffer, C. Berger, T. Pertel, J. Schmitt, and S. Kallis Essential role of cyclophilin A for hepatitis C virus replication and virus production and possible link to polyprotein cleavage kinetics PLoS Pathog 5 2009 e1000546
44. L. Coelmont, S. Kaptein, J. Paeshuyse, I. Vliegen, J.M. Dumont, and G. Vuagniaux Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors Antimicrob Agents Chemother 53 2009 967 976
45. R. Flisiak, J.M. Pawlotsky, R. Crabbe, P.I. Callistru, W. Kryczka, and D. Häussinger Once daily alisporivir (Debio025) plus pegIFNalfa2a/ribavirin results in superior sustained virologic response (SVR) in chronic hepatitis C genotype 1 treatment naive patients J Hepatol 54 2011 24
46. R. Flisiak, S.V. Feinman, M. Jablkowski, A. Horban, W. Kryczka, and M. Pawlowska The cyclophilin inhibitor Debio 025 combined with PEG IFN alpha 2a significantly reduces viral load in treatment-naive hepatitis C patients Hepatology 49 2009 1460 1468
47. P. Ferenci, T.M. Scherzer, H. Kerschner, K. Rutter, S. Beinhardt, and H. Hofer Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy Gastroenterology 135 2008 1561 1567
48. H.L. Janssen, H.W. Reesink, S. Zeuzem, E. Lawitz, M. Rodriguez-Torres, and A. Chen A randomized, double-blind, placebo controlled safety and anti-viral proof of concept study of miravirsen, an oligonucleotide targeting mir-122, in treatment naive patients with genotype 1 chronic HCV infection Hepatology 54 2010 1071
49. E.J. Gane, S.K. Roberts, C.A. Stedman, P.W. Angus, B. Ritchie, and R. Elston Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial Lancet 376 2010 1467 1475
50. Gilead press releases 2012. < http://www.gilead.com/pr-1684792 >.
51. E.J. Gane, C.A. Stedman, R.H. Hyland, R.D. Sorensen, W.T. Symonds, and R. Hindes Once daily PSI-7977 plus RBV: pegylated interferon-alpha not required for complete rapid viral response in treatment-naive patients with HCV Gt2 or Gt3 Hepatology 54 2011 18
52. E. Gane, C.A. Stedman, R.H. Hyland, R.D. Sorensen, W.T. Symonds, and R. Hindes Electron: once daily PSI-7977 plus RBV in HCV Gt1/2/3 J Hepatol 56 2012 438 439
53. S. Zeuzem, T. Asselah, P. Angus, J.P. Zarski, D. Larrey, and B. Mullhaupt Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection Gastroenterology 141 2011 2047 2055
54. S. Zeuzem, A. Soriano, T. Asselah, J.P. Bronowicki, A. Lohse, and B. Müllhaupt SVR4 and SVR12 with an interferon-free regimen of BI201335 and BI207127, +/-ribavirin, in treatment-naive patients with chronic genotype-1 HCV infection: interim results of Sound-C2 J Hepatol 56 2012 45
55. S. Zeuzem, P. Buggisch, K. Agarwal, P. Marcellin, D. Sereni, and H. Klinker The protease inhibitor GS-9256 and non-nucleoside polymerase inhibitor tegobuvir alone, with RBV or peginterferon plus RBV in hepatitis C Hepatology 55 2012 749 758
56. D.R. Nelson, E.J. Gane, I.M. Jacobson, A.M. Di Bisceglie, K. Alves, and M.J. Koziel VX-222/telaprevir in combination with peginterferon-alfa-2a and ribavirin in treatment-naive genotype 1 HCV patients treated for 12 weeks: Zenith study, SVR 12 interim analyses Hepatology 54 2011 1442
57. F. Poordad, E. Lawitz, K.V. Kowdley, G.T. Everson, B. Freilich, and D. Cohen 12-Week interferon-free regimen of ABT-450/R +ABT-333 +ribavirin achieved SVR12 in more than 90% of treatment-naive HCV genotype-1-infected subjects and in 47% of previous non-responders J Hepatol 56 2012 549 550
58. E. Lawitz, F. Poordad, K.V. Kowdley, D.M. Jensen, D. Cohen, and S. Siggelkow 12-Week interferon-free regimen of ABT-450/R, ABT-072, and ribavirin was well tolerated and achieved sustained virologic response in 91% treatment-naive HCVIL28B-CC genotype-1-infected subjects J Hepatol 56 2012 7
59. F. Suzuki, K. Ikeda, J. Toyota, Y. Karino, T. Ohmura, and K. Chayama Dual oral therapy with the NS5A inhibitor daclatasvir (BMS-790052) and NS3 protease inhibitor asunaprevir (BMS-650032) in HCV genotype 1b-infected null responders or ineligible/intolerant to peginterferon/ribavirin J Hepatol 56 2012 7 8
60. M.S. Sulkowski, D.F. Gardiner, E. Lawitz, F. Hinestrosa, D.R. Nelson, and P.J. Thuluvath Potent viral suppression with all-oral combination of daclatasvir (NS5A inhibitor) and GS-7977 (NS5B inhibitor), +/- ribavirin, in treatment-naive patients with chronic HCV GT1, 2, or 3 J Hepatol 56 2012 560
61. M.S. Sulkowski, M. Rodriguez-Torres, E. Lawitz, M. Shiffman, S. Pol, and R. Herring High sustained virologic response rate in treatment-naive HCV genotype 1a and 1b patients treated for 12 weeks with an interferon-free all-oral quad regimen: interim results J Hepatol 56 2012 560
62. J.M. Pawlotsky, S.K. Sarin, G. Foster, C.Y. Peng, J. Rasenack, and R. Flisiak Alisporivir plus ribavirin is highly effective as interferon-free or interferon-add-on regimen in previously untreated HCV-GT2 or GT3 patients: SVR12 results from the VITAL-1 phase 2b study J Hepatol 56 2012 553
63. T.W. Chu, R. Kulkarni, E.J. Gane, S.K. Roberts, C. Stedman, and P.W. Angus Effect of IL28B genotype on early viral kinetics during interferon-free treatment of patients with chronic hepatitis C Gastroenterology 142 2012 790 795
64. S. Gaudieri, A. Rauch, K. Pfafferott, E. Barnes, W. Cheng, and G. McCaughan Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy Hepatology 49 2009 1069 1082
65. T. Kuntzen, J. Timm, A. Berical, N. Lennon, A.M. Berlin, and S.K. Young Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients Hepatology 48 2008 1769 1778
66. C.M. Lange, and S. Zeuzem IL28B single nucleotide polymorphisms in the treatment of hepatitis C J Hepatol 55 2011 692 701
67. C. Hezode, N. Forestier, G. Dusheiko, P. Ferenci, S. Pol, and T. Goeser Telaprevir and peginterferon with or without ribavirin for chronic HCV infection N Engl J Med 360 2009 1839 1850